Tezepelumab: 13 agencies, 2022–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where tezepelumab met resistance it was usually narrowed rather than refused: 8 of 20 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The record spans 3.9 years, opening at PBAC (Australia) in 2022 and running to 19 Jun 2026.
NYE METODER (Norway) changed its position: not recommended on 17 Mar 2024, recommended by 18 Jan 2026, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 19 of 24 records date from 2023 or later.
4 distinct indication wordings are recorded for tezepelumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess tezepelumab, in 2022; PHARMAC (New Zealand) did not open a file until 24 Apr 2025 — a moderate spread of 2.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 8 of 20 decisive outcomes narrowed tezepelumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), DMC (Denmark) and G-BA (Germany) among others.
7 of the 13 agencies here assessed tezepelumab more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
tezepelumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tezepelumab reads 11 recommended, 8 restricted, 1 not recommended and 1 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 May 2026 | Indication extension | SMR substantial · ASMR V | source |
| G-BA (Germany) | 7 May 2026 | Tezspire — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| PHARMAC (New Zealand) | 7 Apr 2026 | Chronic rhinosinusitis with nasal polyps (CRSwNP), after one nasal polyp surgery unless surgery is contraindicated | PTAC advice: High | source |
| NYE METODER (Norway) | 17 Mar 2024 | Tillegg til vedlikeholdsbehandling ved alvorlig astma hos voksne og ungdom i alderen 12 år og eldre som er utilstrekkeli… | not introduced | source |
| PBAC (Australia) | 2022 | Asthma | Not applicable | source |
19 further decisions for tezepelumab, across 13 agencies, are not shown here. They include the most recent record on file, 19 Jun 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 15 further source documents.
Related molecules
- mepolizumab — same ATC class R03D — Obstructive airway diseases
- omalizumab — same ATC class R03D — Obstructive airway diseases
- benralizumab — same ATC class R03D — Obstructive airway diseases
- montelukast — same ATC class R03D — Obstructive airway diseases
- depemokimab — same ATC class R03D — Obstructive airway diseases
- roflumilast — same ATC class R03D — Obstructive airway diseases
Coverage: 24 decisions for tezepelumab from 13 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class R03D — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.